| Stable Isotope- and Mass Spectrometry-based Metabolomics as Tools in Drug Metabolism: A Study Expanding Tempol Pharmacology. | |
| | |
MedLine Citation:
|
PMID: 23301521 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The application of mass spectrometry-based metabolomics in the field of drug metabolism has yielded important insights not only into the metabolic routes of drugs, but has provided unbiased, global perspectives of the endogenous metabolome that can be useful for identifying biomarkers associated with mechanism of action, efficacy, and toxicity. In this report, a stable isotope- and mass spectrometry-based metabolomics approach that captures both drug metabolism and changes in the endogenous metabolome in a single experiment is described. Here the antioxidant drug tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) was chosen because its mechanism of action is not completely understood, and its metabolic fate has not been studied extensively. Furthermore, its small size (MW = 172.2) and chemical composition (C(9)H(18)NO(2)) makes it challenging to distinguish from endogenous metabolites. In this study, mice were dosed with tempol or deuterated tempol (C(9)D(17)HNO(2)) and their urine profiled using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Principal component analysis of the urinary metabolomics data generated a Y-shaped scatter plot containing drug metabolites (protonated and deuterated) that were clearly distinct from the endogenous metabolites. Ten tempol drug metabolites, including eight novel metabolites, were identified. Phase II metabolism was the major metabolic pathway of tempol in vivo, including glucuronidation and glucosidation. Urinary endogenous metabolites significantly elevated by tempol treatment included 2,8-dihydroxyquinoline (8.0-fold, P<0.05) and 2,8-dihydroxyquinoline-β-D-glucuronide (6.8-fold, P<0.05). Urinary endogenous metabolites significantly attenuated by tempol treatment including pantothenic acid (1.3-fold, P<0.05) and isobutrylcarnitine (5.3-fold, P<0.01). This study underscores the power of a stable isotope- and mass spectrometry-based metabolomics in expanding the view of drug pharmacology. |
| | |
Authors:
|
Fei Li; Xiaoyan Pang; Kristopher W Krausz; Changtao Jiang; Chi Chen; John A Cook; Murali Cherukuri Krishna; James B Mitchell; Frank J Gonzalez; Andrew D Patterson |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-10 |
Journal Detail:
|
Title: Journal of proteome research Volume: - ISSN: 1535-3907 ISO Abbreviation: J. Proteome Res. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101128775 Medline TA: J Proteome Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacokinetic evaluation of capecitabine in breast cancer.
Next Document: Molecular and Epidemiological Characterization of Enterobacterial Multidrug-Resistant Strains in Tle...